AEON Aims For Biosimilar Pathway For Lead Candidate In Cervical Dystonia
Firm Meeting With FDA In Q3; Single Approval Targeted For All Botox Indications
California-based clinical-stage firm AEON Biopharma has announced a strategic redirection for its lead product candidate – using the 351(k) biosimilar pathway, with the world-renowned Botox as the reference product.
